Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7

Abstract

We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike ΔH69/V70 in multiple independent lineages, often occurring after acquisition of receptor binding motif replacements such as N439K and Y453F, known to increase binding affinity to the ACE2 receptor and confer antibody escape. In vitro, we show that, although ΔH69/V70 itself is not an antibody evasion mechanism, it increases infectivity associated with enhanced incorporation of cleaved spike into virions. ΔH69/V70 is able to partially rescue infectivity of spike proteins that have acquired N439K and Y453F escape mutations by increased spike incorporation. In addition, replacement of the H69 and V70 residues in the Alpha variant B.1.1.7 spike (where ΔH69/V70 occurs naturally) impairs spike incorporation and entry efficiency of the B.1.1.7 spike pseudotyped virus. Alpha variant B.1.1.7 spike mediates faster kinetics of cell-cell fusion than wild-type Wuhan-1 D614G, dependent on ΔH69/V70. Therefore, as ΔH69/V70 compensates for immune escape mutations that impair infectivity, continued surveillance for deletions with functional effects is warranted.

Cited by papers we hold 25

• Mutations and Evolution of the SARS-CoV-2 Spike Protein · 2022
  Corrected
• COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection · 2022
  No notice
• Drivers of adaptive evolution during chronic SARS-CoV-2 infections · 2022
  No notice
• SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway · 2022
  Corrected
• Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity · 2022
  No notice
• The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance · 2022
  No notice
• The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines · 2022
  No notice
• SARS-CoV-2 Variants, Vaccines, and Host Immunity · 2022
  No notice
• Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma · 2021
  Not checked
• SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera · 2021
  Not checked
• BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel · 2021
  Not checked
• Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 · 2021
  No notice
• Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy · 2021
  No notice
• Face masks effectively limit the probability of SARS-CoV-2 transmission · 2021
  No notice
• Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies · 2021
  Corrected
• Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies · 2021
  No notice
• SARS-CoV-2 within-host diversity and transmission · 2021
  No notice
• A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa · 2021
  No notice
• Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far? · 2021
  No notice
• Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice · 2021
  No notice

and 5 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.